Application
GR 103691 has been used as a D3 receptor antagonist to test its:
- inducing effect on prepulse inhibition (PPI)
- suppressive effect of motor behavior in rats
- inhibitory effect on chemotaxis in newly excysted juvenile C. sinensis (CsNEJs)
Biochem/physiol Actions
GR 103691 increases the monosynaptic “stretch†reflex (MSR) amplitude in mice by its potent D3 receptor antagonist functionality. It inhibits the PD 128,907 mediated γ-aminobutyric acid (GABA) release.
D3 dopamine receptor antagonist.
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
- UPC:
- 41115700
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- G0544-10MG